The present application describes antibody formulations, including monoclonalantibodies formulated in histidine-acetate buffer, as well as a formulationcomprising an antibody that binds to domain II of HER2 (for example,Pertuzumab), and a formulation comprising an antibody that binds to DR5 (forexample, Apomab).